NATHAN HAMBLIN: Open Payments
NPI 1891123550 · SANTA MARIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,530 in 117 payments from 18 companies in 2025. Trend: 2023 $1,782 · 2024 $1,667 · 2025 $2,530
Food & beverage: $2,463Education: $67
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $277 |
| GENZYME CORPORATION | 6 | $241 |
| UCB, Inc. | 10 | $235 |
| Lilly USA, LLC | 10 | $230 |
| E.R. Squibb & Sons, L.L.C. | 14 | $211 |
| Regeneron Healthcare Solutions, Inc. | 7 | $208 |
| Galderma Laboratories, L.P. | 5 | $204 |
| Incyte Corporation | 8 | $158 |
| Janssen Biotech, Inc. | 10 | $145 |
| Amgen Inc. | 11 | $138 |
Products named: DUPIXENT, Bimzelx, SKYRIZI, Sotyktu, OPZELURA, TREMFYA, OTEZLA, EBGLYSS.
Industry payments across CA — which companies pay providers there.
